1Mathijssen R, Alphen R, Verweij J, et al. Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT- 11)[J]. Clin Canc Res, 2001,7(8) :2182-2194.
2Humerickhouse R, Lohrbaeh K, Li L, et al. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2[J]. Cane Res, 2000, 60: 1189-1192.
4Haaz MC, Rivory LP, Riche C, et al. The transformation of irinotecan (CPT-11) to its active rnetabolite SN-38 by human liver microsornes [J]. Naunyn Schmiedebergs Arch Pharmaeol, 1997,356: 257-262.
6Van Ark-Otte J, Kedde MA, Van Der Vijgh WJF, et al. Determinants of CPT-11 and SN-38 activities in human lung cancer cells[J].Br J Cane, 1998, 77: 2171-2176.
7Guichard S, Terret C, Hennebelle L, et al. CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal eolon and liver tissues[J].BrJ Canc, 1999,80: 364-370.
8Danks MK, Morton CL, Krull EJ, et al. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy[J]. Clin Canc Res, 1999,5:917-924.
9Gupta E, Lestingi TM, Miek R, et al. Metabolic fate of irinotecan in humans: correlation of glueuronidation with diarrhea[J].Cane Res, 1994,54:3723-3725.
10Sparreboom A, de Jonge MJ, de Bruijn P, et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients[J].Clin Canc Res, 1998,4:2747-2754.
二级参考文献30
1Cersosmio RJ. Irinotecan: a new antineoplastic agent for the management of colorectal cancer[J].Ann Pharmacother,1998, 32(12) :1324 - 1333.
2Rivory LP, Chatelut E; Canal P ,et al. Kinetics of the in vivo inter-conversion of the carboxylatee and lactone forms of irinoteacan (CPT-11) and of its metabohte SN-38 in patients[J]. Cancer Res,1994, 54(24):6330-6333.
3Ratain MJ. Insights into the phamacokinetics and pharmacodynamics of irinotecan[J]. Clin Cancer Res. 2000, 6(9) : 3393 - 3394.
4De Bruijn P, Verweij J,Loos WJ,et al.Determination of irinotecan(CPT-11 )and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection[J]. Chromatogr B Biomed Sci Appl, 1997, 698 ( 1/2 ) : 277-228.
5Escoriaza J, Aldaz A, Castellanos C,et al. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid Chromatography: application to clinical pharmacokinetic studies[J]. J Chromatogr B Biomed Sci Appl . 2000. 740(2) :159-168.
6Ragot S, Marquet P, Lachatre F,et al.Sensitive determination of irinotecan (CVF-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry [ J]. J Chromatogr B Biomed Sci Appl,1999, 7.36(1/2) : 175 - 184.
7Saita T, Fujito H, Mori M. Development of ELISAs for irinotecan and its active metabolite SN-38[J].Biol Pharm Bull, 2000, 23(8):911-916.
8Chabot GG, Abrigerges D, Catimel G et al. Population pharmacokinetics and pharmacodynamics of irinotecan(CPT-11) and active metabolite SN-38 during phase Ⅰ trials[J]. Arm Oncol, 1995, 6(2) : 141 - 151.
9Ma MK, McLeod HL.Lessons learned from the metabolic pathway[J]. Curr Med Chem, 2003, 10(1):41 - 49.
10Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis[J]. Cancer Res, 2000, 60(24):6921 -6926.
4FLORIS A de Jong, MAJA JA de Jonge, JAAP Verweij, et al. Role of pharmacogenetics in irinotecan therapy[J]. Cane Lett,2006,234(1) : 90-106.
5Ron HJ Mathijssen, Robbert J van Alphen, Jaap Verweij, et al. Clinical pharmaeokineties and metabolism of irinoteean (CPT-11)[J].Clin Cane Res, 2001,7 (8) : 2182-2194.
6Norimasa Kaneda, Hiroshi Nagata, Tornio I-unita, et al. Metabolism and pharmacokinetics of the camptothetin analogue CPT-11 in the mouse [J]. Cane Res, 1990, 50(6) : 1715-1720.
7Akinobu Kurita, Norimasa Kaneda. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system[J].J Chromatogr B Biomed Sci Appl,1999, 724(2):335-344.
8Peter de Bruijn, Jaap Verweij, Walter J Loos, et al. Determination of irinoteean (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase highperformance liquid chromatography with fluorescence detection[J].J Chromatogr B Biomed Sci Appl, 1997, 698(1/2) :277-285.
9Peter de Bruijn, Jaap Verweij, Walter J Loos, et al. Determination of irinotecan (CPT-11) and its active metabolite SN- 38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection[J]. J Chromatogr B Biomed Sci Appl, 1997,689 (1/2) : 277-285.
10Bansal T, Awasthi A, Jaggi M, et al. Development and validation of re- versed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan ( CPT-11 ) and its active metabolite, SN- 38,in rat plasma and bile samples:application to pharmacokinetic studies [J]. Talanta,2008 ;76 ( 5 ) : 1015-21.
